Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

C

Central Hospital, Nancy, France

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

27

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Eating Disorders in Patients With Phenylketonuria

EValuation of Cardiac Magnetic Resonance Imaging in Follow up assessmenT of Patients With Pulmonary Arterial Hypertension (EVITA)

Earlier

Jun 26, 2026TrialTumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Jun 26, 2026TrialGATED-PET Heart Analysis in Patients Having a Gallium-68--DOTATOC PET/CT Exam for Oncology Indication

Jun 26, 2026TrialCombination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

Jun 26, 2026TrialEvaluation of the Use of Machine Learning Techniques to Classify Neurodegenerative PARKinsonian Syndromes (Artificial Intelligence)

Jun 26, 2026TrialEvaluation of an Artificial Intelligence Algorithm Reducing Noise on Fast Whole-body Bone Tomoscintigraphy Acquisitions Recorded by a 360 Degree Cadmium-Zinc-Tellurid Camera

Jun 26, 2026TrialMonocentric Interventionnal Pilot Study Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis

2 more events

Jun 26, 2026TrialExperience of PLUVICTO (PSMA-617 Labelled With Lutetium-177) Administration on Totally Implantable Venous Access Port (TIVAP)

Jun 26, 2026TrialComparison of Changes in Tumor Burden (Toral Tumor Volume [TMTV] and Total Lesion Activity [TLA]) in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)